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Abstract
Introduction—HF may contribute to the development of functional decline and frailty in older
adults.
Methods—Sixty HF patients with EF ≤ 40% evaluated in 2004–5 were reevaluated in 2008. Six-
minute walk distance (6MW), frailty score, and biomarkers (25-hydroxyvitamin D, C-reactive
protein and interleukin-6[IL6]) were measured. Participants were categorized at baseline and
follow-up into 3 groups: non-frail/normal endurance (NF/NE), non-frail/low endurance (NF/LE)
and frail/low endurance (F/LE). Survival time was assessed according to frailty/endurance status
and associated predictors of mortality.
Results—Forty-three men, 17 women (mean age 78±12) were contacted. At follow up 20 died,
20 participated and 20 did not participate. There were no changes in frailty/endurance status over
time (McNemar; p=0.19). Deaths occurred in 18% of NF/NE, 45% of NF/LE and 60% of F/LE.
NF/NE had greater survival rates than NF/LE (p=.032) and F/LE (p=.014). The 6MW and frailty
score were independently predictive of mortality with hazard ratio.82(.72–.94) and 1.64(1.19–
2.26) respectively, as was NYHA and IL6. Backward stepwise Cox- regression revealed that
6MW and frailty each were associated with mortality (p=0.005) and highly correlated.
Conclusions—Physical function is an important predictor of mortality in older adults with HF.
The 6MW may be useful as a measure of frailty.
Introduction
Heart failure is the most rapidly increasing cardiovascular disease in the US and the primary
discharge diagnosis for Medicare recipients. There are approximately 5.7 million people
who have the diagnosis of HF in the US.1 Heart failure constitutes the most common cause
for re-hospitalization and has been identified by the Medicare Payment Advisory
Commission as the highest cost to the healthcare system.2, 3 Hospitalizations of older
patients can result in functional deterioration leading to dependency and disability.4, 5 Due
to the unpredictable trajectory of heart failure exacerbations it is difficult to discern which
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patients are at the greatest risk for repeat hospitalizations, functional decline and mortality.
The frailty syndrome defined as a poor ability to cope with physiological stress, has
demonstrated a strong association with a diagnosis of heart failure in observational studies.
5–9 Frail patients with or without heart failure often experience functional decline and have
an increased risk of death compared to their more robust counterparts. The difficulty has
been to identify patients who are frail in order to increase resources available to these
patients in hopes of improving health outcomes. There is no direct clinical test to measure
frailty, and the challenge is to identify proxy measures which can serve as an indicator of
this vulnerable state. Since heart failure and frailty have an association, patients with heart
failure are an ideal population to study to further understand frailty.
We have previously found an association between frailty, poor endurance, vitamin D, and C-
reactive protein in a cross-sectional analysis of patients with heart failure.10 This study is a 4
year follow up of the original cohort of patients to determine if measures of frailty and
endurance are useful predictors of outcomes in older patients with heart failure.
Methods
The study was reviewed and approved by the Institutional Review Board at the University of
Connecticut Health Center (UCHC). Participants were recruited from UCHC Heart Failure
Center. Informed consent was obtained from each participant. Baseline inclusion criteria
included patient's age ≥ 60 years with heart failure who received their care in a heart failure
program and an ejection fraction (EF) of ≤ 40% measured by echocardiogram, cine
angiography, or radionuclide angiography within the preceding year. Patients were excluded
at baseline if they had serious end stage disease of another organ system, disorders that
greatly affected ambulation, and hormonal therapy known to affect muscle function.
Exclusion criteria included: metastatic, active, or advanced cancer, active chemotherapy,
radiation treatment, or hormonal therapy, systemic rheumatologic or connective tissue
disorders, consumption of more than three alcoholic drinks per day, use of androgen,
estrogen, DHEA, or hormone receptor antagonists in the preceding year, or had advanced
liver disease, renal disease requiring dialysis, Parkinson's disease, an inability to ambulate,
or a myocardial infarction within three months prior to the study.
Frailty Phenotype Score
The Frailty Phenotype score (frailty score)5, a multi-domain research tool to quantify frailty
was selected because it was validated in a large population of community dwelling older
adults (≥ age 65 years) from the Cardiovascular Health Study. The frailty score was found to
overlap measures of disability and co-morbidity but also independently predicted disability,
hospitalization and death over 3 years. The frailty score includes self-reported weight loss of
≥ ten pounds in the preceding year, grip strength measured by hand-held Jamar
dynamometer, sense of exhaustion as evaluated by two questions from the Center of
Epidemiologic Studies-Depression Scale,11 walking speed by an 8-foot walk, and level of
physical activity reported in kcals/week from the Physical Activity Scale in the Elderly
(PASE).12 The scoring of each measure according to cut-off values to determine the total
frailty score is described elsewhere.5 The results of the tests were dichotomized to identify
non-frail (NF) with 0–2/5 characteristics, or frail (F) with ≥ 3 characteristics.
6- Minute Walk
The 6-minute walk test protocol was performed as previously published.13 Participants were
permitted to use a walker or cane if needed while the observer recorded symptoms such as
chest pain, shortness of breath or leg pain. Participants were categorized into two groups
according to the performance on the test. Those walking ≤ 300 meters were classified as
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having low endurance (LE), and those walking > 300 meters were classified as normal
endurance (NE). The cutoff of 300 meters was chosen because of its use as a cutoff in
SOLVD (Studies of Left Ventricular Function) as well as others.14–16
Biochemical Measurements
Serum was divided into 0.5 ml aliquots and stored at −70°C. Interleukin-6 was measured
with an intra-assay CV of 3.4 % and C-reactive protein with an intra-assay variation of
3.3%. Vitamin D as 25-hydroxyvitamin D (25OHD) measurement was measured by enzyme
immunoassay (Immunodiagnostic Systems Inc.,Fountain Hills, AZ), with an intra-assay CV
of less than 6.6%. The N-Terminal prohormone B-Type Natriuretic Peptide was measured
by ELISA (Alpco Diagnsostics, Windham, NH) with an intraassay CV of 5.3%. Blood urea
nitrogen, creatinine and hemoglobin were measured in the clinical laboratory of the
University of Connecticut Heath Center, Farmington, CT.
Follow up Assessments
Original participants were contacted in 2008. Subjects were re-contacted by letter or during
their routine cardiology appointments to consider further participation in the study. Deaths
were confirmed by clinical notes and death records. Of the 60 original participants 20
participated in the second assessment, 20 were deceased, and 20 did not participate. Those
who participated underwent a frailty score assessment and 6 minute walk test. Participants
were reclassified into frailty and endurance subgroups as described above.
Statistical Analysis
Kaplan-Meier method was used to assess survival time distribution according to frailty/
endurance status. Status was defined as the 3 category descriptor of frailty and endurance;
nonfrail/normal endurance (NF/NE), nonfrail/low endurance (NF/LE), frail/low endurance
(F/LE). F/NE (frail/normal endurance) was excluded from the analysis as only one subject
fit this category). The time to event or survival time was calculated as the number of days
from the first exam date to the endpoint date. Death was defined as the primary endpoint,
while censored events were the dates participants were contacted for follow up assessments.
Subjects without follow-up contact were verified as living and a mean date of the
participating subjects' dates was added as an endpoint. Log rank pairwise comparison tests
were used to detect differences in survival time (days) between each of the 3 frailty/
endurance status categories. Univariate Cox regression models, adjusted for age, were used
to detect if vitamin D, CRP levels, ischemia, hemoglobin, creatinine, ejection fraction heart
history, NTproBNP, NYHA classification and interleukin 6 were associated with survival
time. Based only on significant predictors of mortality from the univariate models, we
performed a multivariate Cox regression model including age (5 year categories), CRP
levels, NYHA classifications, interleukin 6, six minute walk distance (30 meter categories),
and frailty score. To adjust for the high collinearity between six minute walk distance and
frailty score, each of the latter variables mentioned were included without the other in two
separate backwards stepwise Cox regression models. A McNemar test of agreement was
used to assess if frailty/endurance status changed from baseline assessments to follow-up.
All statistics were evaluated using SPSS 16.0 software (SPSS Inc., Chicago, IL).
Significance was noted as p values <0.05.
Results
Twenty deaths were reported of the original 60 heart failure participants prior to study
follow-up assessment. Twenty did not participate (4 had serious long term health problems,
3 moved out of state, 13 did not respond to contact). Twenty underwent the 4 year
assessment. Individuals who did not participate in the 4 year follow-up visit were not
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different in baseline characteristics compared to follow up participants or deceased
participants (Table 1). However, non-participants appeared intermediate in frailty score and
6-minute walk distance between deceased subjects compared to 4 year follow-up
participants. This did not reach statistical significance.
At baseline, the participants categorized as NF/NE were younger and performed
significantly better on all components of the frailty score as well as distance walked in 6
minutes. On average, individuals did not transition from one endurance/frailty category to
another (McNemar test; p=0.19; Figure 1).
With regard to mortality, of those characterized as NF/NE at baseline, 18% died, NF/LE
45% died, and F/LE 60% died. (Figure 1) The NF/NE group had significantly longer
survival than the other two groups (1481 days; p<.05 for both) by Kaplan Meier analysis.
However, the survival time for NF/LE (1219 days) and the F/LE (1222 days) were not
different (p = .85) (Figure 2). In univariate analysis, shorter 6-minute walk distance, higher
frailty score, higher CRP, higher IL6 levels, and higher NYHA class were significantly
associated with higher mortality rates (Table 2). Vitamin D, ischemia, hemoglobin,
creatinine, ejection fraction, NTproBNP were evaluated and not associated with mortality.
Including only variables that were significant in the univariate analysis, two multivariate
backwards stepwise Cox regressions were performed. The 6-minute walk and frailty score
were highly negatively correlated, and therefore, collinear in the models (data not shown). In
order to account for high collinearity, 6-minute walk and frailty were included in separate
models. Increasing one frailty category meant individuals were more than 1.5 times more
likely to be deceased (Table 3a). Decreasing walk distance by 30 meters meant individuals
were 19% more likely to be deceased. (Table 3b). Each of these factors was important and
significant in predicting mortality rates.
Discussion
In this study of 59 older patients with systolic HF, both the frailty score and 6-minute walk
distance were independently predictive of mortality. Albeit the HR are small, with the HR
for frailty of 1.58 and for the 6-minute walk .84. Many studies in patients with heart failure
have shown an association between 6-minute walk distance and mortality.15, 17, 18 Our
work has shown that the frailty score and 6-minute walk were highly correlated (r= −.72),
and were in moderate agreement in patients with HF(kappa 0.57, 95% CI = (0.37, 0.77)19, In
Cox regression modeling, the two measures are collinear and likely capture different but
overlapping phenomenon. Frailty is a measure of increased vulnerability to adverse outcome
and the 6-minute walk is a measure of functional ability and aerobic capacity. These two
measures together can theoretically capture the most at risk patients for adverse events and
decline in physical function. The Kaplan-Meier curve captures this in the survival analysis;
those who are frail combined with low endurance have the highest mortality.
The change over time in this cohort of patients seen in Figure 1 demonstrates that those that
remain in the NF/NE at baseline may have the best prognosis. Although 9% of those patients
moved to the NF/LE category, our numbers are too small for this to reach statistical
significance. Over the 4 year study period we expected more of these patients to decline and
move out of the NF/NE category. We were under the assumption that the majority of older
patients with heart failure would physically decline. Although, it is unknown if heart failure
patients, regardless of age, decline in function over time. Individual specific markers of
stability and/or decline may be important in order to design appropriate interventions.
The 6-minute walk distance is a frequently used and easily administered test to assess
patients with heart failure. Walk tests are often part of a battery of tests to assess older adults
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and have been correlated with multiple domains of function and outcome.20–22 Interpreting
the 6-minute walk with a distance of ≤ 300 meters as a valid measure of frailty may broaden
the accessibility of a frailty diagnosis into the cardiologist's office. Recognition of frailty can
alert the physician that the patient may benefit from a multidisciplinary geriatric care
setting23 and/or an exercise prescription. To date, exercise is the only accepted frailty
“therapy” and may improve the outcome for these patients.24, 25
Strategies to reverse the frail state have been an area of intense research. Restoration of
physical function through resistance training has shown benefit in frail older adults.24–27
Exercise training in patients with heart failure has been evaluated in multiple small studies28
and recently in the multi-center HF ACTION trial (A Randomized Controlled Trial
Investigating Outcomes of Exercise Training) in 2331 participants. In addition to tolerability
and safety of aerobic exercise, the results of the trial included significant improvement in the
6-minute walk distance, and improved health status, but no changes in all cause mortality or
hospitalization.29, 30 Although it is unclear if aerobic exercise has an impact on the frail
state, the changes seen early in this study on the 6-minute walk distance are encouraging.
Cross-sectional analysis of this cohort had indicated that the biomarkers CRP and vitamin D
were indicative of functional status in patients with heart failure.10 In longitudinal univariate
analysis these measures were predictive of death (as was NYHA class). Although in
multivariate analysis, these biomarkers were surpassed by the two functional measures,
frailty and the 6-minute walk. This implies that measures of physical function have an
important role in predicting outcome in older heart failure patients and should not be
forgotten in the wave of serum biomarkers research. This data may suggest that CRP and
vitamin D are intermediary markers to the more robust 6-minute walk or frailty markers.
Studies of vitamin D in older adults have demonstrated that higher vitamin D levels or
repletion with vitamin D are associated with improvement in muscle strength, walking
distance, decreased fall frequency and improved balance/body sway.31–34 Cross-sectional
analysis of CRP and functional status established an association between CRP and function,
35 but longitudinal studies of the effects of CRP change on functional status are not
available.
Few prospective studies have evaluated frailty in patients with heart failure even though the
two syndromes have a well recognized relationship. The majority of frailty research has
been in community dwelling older adults, and this research has consistently identified a link
between cardiovascular disease and frailty7, 36. Caccitore et al. measured frailty in patients
with heart failure using the Frailty Staging System. This instrument enlists a multi-domain
approach by history and physical exam which can easily be performed in the physician's
office. It includes questions to determine ADLs, urinary incontinence, depression, cognitive
function and social supports as well as simple physical testing for mobility, vision, and
hearing. Although this measure captures multiple domains of function, it does not include
any direct measurement of aerobic capacity or endurance. This staging system includes
measures that are not routinely used in the cardiologist's office and may be more appropriate
in the primary care setting. This frailty measure was found to be a stronger predictive of
long term mortality at 9 years in an older cohort of heart failure patients than those without
heart failure.37
The ability of heart failure participants in the NF/NE group to maintain their function and
endurance over the 4 years suggests that this subgroup of individuals may warrant a multi-
faceted intervention to maintain physical capacity and reserve. Maintaining and/or restoring
physical function through exercise may be the cornerstone of reversing frailty in chronically
ill older adults. The challenge will be how to initiate and maintain exercise training in these
patients.
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A diagnosis of heart failure confers a risk for functional decline and disability. Identification
of patients at the highest risk for functional decline remains difficult due to the unpredictable
trajectory of chronic heart failure. Measures of function which capture the multi-
dimensional features of frailty can provide a valuable clinical tool for the management of
older patients with heart failure.
Limitations of the Study
This study has limitations. The sample size is small and these results need confirmation in a
larger sample. In addition, a significant number of individuals were not able to be contacted
in follow up. The mortality data was not affected by those that could not be contacted, but
follow-up information on function would be. The functional status of those lost to follow-up
at baseline appears intermediate between those that died and those willing to be reassessed,
suggesting functional ability in this subgroup may not be maintained as well as those for
which we have data. Further, our sample was too small to evaluate our frailty assessment as
an ordinal measure by more then a dichotomy. Future studies will need to address this
intermediate group in alternate ways, possibly with home visits or less cumbersome testing.
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Figure 1.
Functional Group from Baseline to 4 Years
NF/NE = non-frail/normal endurance, NF/LE = non-frail/low endurance, F/LE = frail/low
endurance
Boxer et al. Page 9
Congest Heart Fail. Author manuscript; available in PMC 2011 January 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Kaplan-Meier Survival Curve for 59 Heart Failure Subjects categorized by endurance and
frailty followed for 4 years
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Table 2
Univariate predictors of death adjusted for age (yrs)
Hazard ratio 95% CI p value
Six min walk distance (30m) 0.82 0.72 – 0.94 .004
Frailty Phenotype score 1.64 1.19 – 2.26 .003
Ejection Fraction 1.003 .945 – 1.064 .926
NYHA Class 2.42 1.16 – 5.07 .019
Ischemia as cause of heart failure .685 .188 – 2.492 .566
NT-Pro-BNP (fmol/L) 1.00 999 – 1.001 .888
hsCRP (mg/dL) 1.12 0.99 – 1.25 .062
IL6 (mg/dL) 1.06 1.00 – 1.11 .035
Vitamin D (ng/mL) .99 .969 – 1.004 .123
Creatinine (mg/dL) 1.16 .431 – 3.14 .767
Hemoglobin (g/dL) .782 543 – 1.126 .186
P values based on cox regression survival analyses
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